NASDAQ:ONCS - OncoSec Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.50 -0.02 (-3.85 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$0.53
Today's Range$0.50 - $0.54
52-Week Range$0.42 - $2.21
Volume256,500 shs
Average Volume544,246 shs
Market Capitalization$32.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; and a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.38 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

EmployeesN/A
Market Cap$32.40 million
Next Earnings Date3/22/2019 (Estimated)
OptionableNot Optionable

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) released its quarterly earnings results on Wednesday, October, 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. View OncoSec Medical's Earnings History.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for OncoSec Medical.

What price target have analysts set for ONCS?

4 Wall Street analysts have issued 1 year target prices for OncoSec Medical's shares. Their forecasts range from $3.00 to $5.00. On average, they expect OncoSec Medical's share price to reach $4.00 in the next year. This suggests a possible upside of 700.0% from the stock's current price. View Analyst Price Targets for OncoSec Medical.

What is the consensus analysts' recommendation for OncoSec Medical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.

Has OncoSec Medical been receiving favorable news coverage?

Media headlines about ONCS stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoSec Medical earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the near future.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
  • Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.75%), Geode Capital Management LLC (0.60%), Geode Capital Management LLC (0.60%), Northern Trust Corp (0.18%), Bank of New York Mellon Corp (0.16%) and Moloney Securities Asset Management LLC (0.08%). Company insiders that own OncoSec Medical stock include Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon and Richard B Slansky. View Institutional Ownership Trends for OncoSec Medical.

Which institutional investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold OncoSec Medical company stock in the last year include Avtar S Dhillon, Punit Dhillon and Richard B Slansky. View Insider Buying and Selling for OncoSec Medical.

Which institutional investors are buying OncoSec Medical stock?

ONCS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Bank of New York Mellon Corp, Northern Trust Corp and Moloney Securities Asset Management LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor, James M Demesa and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $0.50.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $32.40 million.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is http://www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]


MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel